Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Temporary Exclusion for 100% of Gain from Qualified Small Business Stock Extended Through 2011

Related Content

BMS and Ono File BPCIA Suit Against Amgen for Nivolumab Biosimilar

Cipla and Qilu Announce Exclusive U.S. Licensing and Supply Agreement for Pembrolizumab Biosimilar

Preparing for the EU Cyber Resilience Act: Key Reporting Obligations From 11 September 2026

The DTSA at Ten: Lessons From a Decade of DTSA Litigation

ITC Trade Secret Litigation: An Underused Forum

Courts Expand the DTSA’s Reach to Foreign Trade Secret Misappropriation Following Motorola v. Hytera

Biocon Enters Ten-Year Pertuzumab Supply Contract in Brazil

FDA Sharpens Its Pencil and Oversight Tools on Global Clinical Trial Data

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Guides Dualitas Therapeutics on Research Collaboration With Roche to Discover and Develop Novel Bispecific Antibodies for I&I Diseases

Goodwin Advises Marea Therapeutics on Acquisition by Lisata Therapeutics and $225 Million Concurrent Private Placement

Goodwin Advises Alpha Wave on Investment in Moonwalk Biosciences’ $70M Series B Financing Round

Goodwin Earns Record Number of Honors at 2026 LMG Life Sciences Americas Awards

Goodwin Advises DualityBio on Global Collaboration and License Agreement With Genentech

Goodwin Strengthens Life Sciences and Public M&A Platform With Partner Ro Park

Goodwin Advises Mission BioCapital on Securing Eligibility for $44.5 Million Non-Dilutive Funding Through AMED Program

Life Sciences

Investment Funds and Capital

Technology

Private Equity

Tax